Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bone hydroxyapatite is the primary inorganic mineral component of bone and teeth, consisting of a crystalline calcium phosphate matrix with the chemical formula Ca10(PO4)6(OH)2. It provides structural rigidity, compressive strength, and mechanical support to the skeletal system, while also serving as a reservoir for calcium and phosphate ions to maintain systemic mineral homeostasis. In pharmacological contexts, the bone hydroxyapatite surface is a critical therapeutic target for bone-targeting drugs, particularly bisphosphonates and bone-seeking radiopharmaceuticals. Bisphosphonates, such as alendronate and zoledronic acid, bind avidly to hydroxyapatite crystals at sites of active bone remodeling. Upon osteoclast-mediated bone resorption, the local acidic environment dissolves the mineral matrix, releasing the drugs to be internalized by osteoclasts, where they inhibit key metabolic pathways and induce apoptosis to prevent bone loss. Additionally, bone-seeking radiopharmaceuticals like radium-223 and samarium-153 target hydroxyapatite to deliver localized cytotoxic radiation to bone metastases, making this mineral surface a cornerstone for treating osteoporosis, Paget's disease, and skeletal malignancies.
Bisphosphonates bind with high affinity to bone hydroxyapatite crystals, particularly at sites of active bone remodeling. During osteoclast-mediated bone resorption, the local acidic environment dissolves the hydroxyapatite mineral, releasing the bisphosphonates. The released drugs are internalized by osteoclasts via fluid-phase endocytosis, where they inhibit farnesyl pyrophosphate synthase (nitrogen-containing bisphosphonates) or form cytotoxic ATP analogs (non-nitrogen-containing bisphosphonates), ultimately inducing osteoclast apoptosis and reducing bone resorption. Bone-seeking radiopharmaceuticals mimic calcium or bind directly to hydroxyapatite, delivering localized ionizing radiation to destroy cancer cells in bone metastases.
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bone hydroxyapatite (HA).